Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 12 (April 20), 2007: pp. 1545-1552
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.1474

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gatzemeier, U.
Right arrow Articles by Von Pawel, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gatzemeier, U.
Right arrow Articles by Von Pawel, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Ulrich Gatzemeier, Anna Pluzanska, Aleksandra Szczesna, Eckhard Kaukel, Jaromir Roubec, Flavio De Rosa, Janusz Milanowski, Hanna Karnicka-Mlodkowski, Milos Pesek, Piotr Serwatowski, Rodryg Ramlau, Terezie Janaskova, Johan Vansteenkiste, Janos Strausz, Georgy Moiseevich Manikhas, Joachim Von Pawel

From the Zentrum Fur Pneumologie Und Thoraxchirurgie, Krankenhaus D LVA; Pneumology, Hospital Harburg, Hamburg; Asklepios Fachkliniken Muenchen-Gauting, Onkologie, Gauting, Germany; Chemotherapy Clinic, Medical Academy of Lodz, Lodz; Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy, Oddzial III, Otwock; Akademia Medyczna W Lublinie, Karedra I Klinika Chorob Pluc, Lublin; Oddzial Chemioterapii, Szpital Morski Im. Pck, Gdynia; Specjalistyczny Szpital Im., Oddzial Chemioterapii, Szczecin; Wielkopolskie Centrum Chorób Pluc i Grurlicy, Poznan Poland; Klinika TBC a Respiracnich Onemocneni, Ostrava-Poruba, Czech Republic; F. Hoffmann-La Roche, Basel, Switzerland; Fakultni Nemocnice V Plzni, Plicni Klinika, Plzen; Vitkovicka Nemocnice Bma A.S., Plicni Oddeleni, Ostrava, Czech Republic; Department of Pulmonary Medicine, Universitair Ziekenhuis Leuven, Leuven, Belgium; 2nd Department of Pulmonary Medicine, Institute of Pulmonary Medicine Torokbalint, Torokbalint, Hungary; and the Pulmonary Department, St Petersburg City Oncological Dispensary, St Petersburg, Russian Federation

Address reprint requests to Ulrich Gatzemeier, MD, Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; e-mail: pneumo.onko{at}t-online.de

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated the efficacy and safety of erlotinib in combination with cisplatin and gemcitabine as first-line treatment for advanced non–small-cell lung cancer (NSCLC).

Patients and Methods Patients received erlotinib (150 mg/d) or placebo, combined with up to six 21-day cycles of chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1). The primary end point was overall survival (OS). Secondary end points included time to disease progression (TTP), response rate (RR), duration of response, and quality of life (QoL).

Results A total of 1,172 patients were enrolled. Baseline demographic and disease characteristics were well balanced. There were no differences in OS (hazard ratio, 1.06; median, 43 v 44.1 weeks for erlotinib and placebo groups, respectively), TTP, RR, or QoL between treatment arms. In a small group of patients who had never smoked, OS and progression-free survival were increased in the erlotinib group; no other subgroups were found more likely to benefit. Erlotinib with chemotherapy was generally well tolerated; incidence of adverse events was similar between arms, except for an increase in rash and diarrhea with erlotinib (generally mild).

Conclusion Erlotinib with concurrent cisplatin and gemcitabine showed no survival benefit compared with chemotherapy alone in patients with chemotherapy-naïve advanced NSCLC.

Supported by F. Hoffmann-La Roche Ltd.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in Medical OncologyHome page
C. Schettino, M. A. Bareschino, A. Rossi, P. Maione, V. Castaldo, N. Mazzeo, P. C. Sacco, M. L. Ferrara, G. Palazzolo, F. Ciardiello, et al.
Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer
Therapeutic Advances in Medical Oncology, July 1, 2009; 1(1): 5 - 13.
[Abstract] [PDF]


Home page
Anticancer ResHome page
S. D. RICE, J. E. BUSH, and S. L. BROWER
Assessment of Erlotinib in Chemoresponse Assay
Anticancer Res, June 1, 2009; 29(6): 1993 - 1997.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, et al.
Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
Anticancer Res, May 1, 2009; 29(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Grossi, M. Aita, C. Defferrari, F. Rosetti, A. Brianti, G. Fasola, O. Vinante, P. Pronzato, and G. Pappagallo
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Oncologist, May 1, 2009; 14(5): 497 - 510.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
G. K. Dy and A. A. Adjei
Emerging Therapeutic Targets in Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 218 - 223.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
T. E. Stinchcombe and M. A. Socinski
Current Treatments for Advanced Stage Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Staal, M. J. O'Connell, and C. J. Allegra
The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust?
J. Clin. Oncol., April 1, 2009; 27(10): 1545 - 1548.
[Full Text] [PDF]


Home page
The OncologistHome page
N. A. Pennell and T. J. Lynch Jr.
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Oncologist, April 1, 2009; 14(4): 399 - 411.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Langer
The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
J. Clin. Oncol., March 20, 2009; 27(9): 1350 - 1354.
[Full Text] [PDF]


Home page
JCOHome page
M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, et al.
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
J. Clin. Oncol., March 10, 2009; 27(8): 1227 - 1234.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. Gridelli, P. Maione, A. Rossi, M. L. Ferrara, M. A. Bareschino, C. Schettino, P. C. Sacco, and F. Ciardiello
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Oncologist, February 1, 2009; 14(2): 137 - 147.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. J. Riely, N. A. Rizvi, M. G. Kris, D. T. Milton, D. B. Solit, N. Rosen, E. Senturk, C. G. Azzoli, J. R. Brahmer, F. M. Sirotnak, et al.
Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 264 - 270.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
M. A. Socinski
What Guides Decisions about the Use of Epidermal Growth Factor Receptor Antibody or Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer?
ASCO Educational Book, January 1, 2009; 2009(1): 436 - 443.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Takano, T. Fukui, Y. Ohe, K. Tsuta, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, K. Furuta, et al.
EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
J. Clin. Oncol., December 1, 2008; 26(34): 5589 - 5595.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. V. Heymach, L. Paz-Ares, F. De Braud, M. Sebastian, D. J. Stewart, W. E.E. Eberhardt, A. A. Ranade, G. Cohen, J. M. Trigo, A. B. Sandler, et al.
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2008; 26(33): 5407 - 5415.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan
Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer
Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
R. S. Herbst and A. Sandler
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Oncologist, November 1, 2008; 13(11): 1166 - 1176.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. R. Hirsch, M. Varella-Garcia, R. Dziadziuszko, Y. Xiao, S. Gajapathy, M. Skokan, M. Lin, V. O'Neill, and P. A. Bunn Jr.
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6317 - 6323.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
J. Clin. Oncol., July 10, 2008; 26(20): 3351 - 3357.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells
Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Morgillo, E. Martinelli, T. Troiani, G. Laus, S. Pepe, C. Gridelli, and F. Ciardiello
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C{beta} inhibitor, in non-small cell lung cancer cells
Mol. Cancer Ther., June 1, 2008; 7(6): 1698 - 1707.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Kelly, K. Chansky, L. E. Gaspar, K. S. Albain, J. Jett, Y. C. Ung, D. H.M. Lau, J. J. Crowley, and D. R. Gandara
Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023
J. Clin. Oncol., May 20, 2008; 26(15): 2450 - 2456.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
V. L. Keedy, C. L. Arteaga, and D. H. Johnson
Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux
J. Clin. Oncol., May 20, 2008; 26(15): 2428 - 2430.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J. Fidler, A. Argiris, J. D. Patel, D. H. Johnson, A. Sandler, V. M. Villaflor, J. Coon IV, L. Buckingham, K. Kaiser, S. Basu, et al.
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Clin. Cancer Res., April 1, 2008; 14(7): 2088 - 2094.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
E. Giovannetti, C. Lemos, C. Tekle, K. Smid, S. Nannizzi, J. A. Rodriguez, S. Ricciardi, R. Danesi, G. Giaccone, and G. J. Peters
Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
Mol. Pharmacol., April 1, 2008; 73(4): 1290 - 1300.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]


Home page
JCOHome page
C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky
Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials
J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O'Byrne, T. Welte, R. Kolb, et al.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Ann. Onc., February 1, 2008; 19(2): 362 - 369.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. A. Bunn Jr. and N. Thatcher
Conclusion
Oncologist, January 1, 2008; 13(suppl_1): 37 - 46.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. A. Butts, D. Bodkin, E. L. Middleman, C. W. Englund, D. Ellison, Y. Alam, H. Kreisman, P. Graze, J. Maher, H. J. Ross, et al.
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer
J. Clin. Oncol., December 20, 2007; 25(36): 5777 - 5784.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA, July 4, 2007; 298(1): 70 - 82.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online